• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝癌免疫微环境：髓系细胞分析的新概念及其诊断和治疗意义

The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications.

作者信息

Arvanitakis Konstantinos, Mitroulis Ioannis, Chatzigeorgiou Antonios, Elefsiniotis Ioannis, Germanidis Georgios

机构信息

First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.

Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education (BRESU), Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.

出版信息

Cancers (Basel). 2023 Feb 28;15(5):1522. doi: 10.3390/cancers15051522.

DOI:10.3390/cancers15051522
PMID:36900313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10000678/
Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide [...].

摘要

肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一[...]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300d/10000678/ee1079b075b5/cancers-15-01522-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300d/10000678/ee1079b075b5/cancers-15-01522-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/300d/10000678/ee1079b075b5/cancers-15-01522-g001.jpg

相似文献

1
The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications.肝癌免疫微环境：髓系细胞分析的新概念及其诊断和治疗意义
Cancers (Basel). 2023 Feb 28;15(5):1522. doi: 10.3390/cancers15051522.
2
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.免疫检查点抑制剂在 HCC 中的应用：细胞、分子和系统数据。
Semin Cancer Biol. 2022 Nov;86(Pt 3):799-815. doi: 10.1016/j.semcancer.2022.01.005. Epub 2022 Jan 19.
3
Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.基于肝癌微环境构建风险评分预后模型。
World J Gastroenterol. 2020 Jan 14;26(2):134-153. doi: 10.3748/wjg.v26.i2.134.
4
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?肝癌中的肿瘤相关巨噬细胞：是敌是友？
Gut Liver. 2021 Jul 15;15(4):500-516. doi: 10.5009/gnl20223.
5
Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.靶向细胞因子诱导的杀伤细胞与髓系来源抑制细胞在肝癌中的相互作用。
J Hepatol. 2019 Mar;70(3):449-457. doi: 10.1016/j.jhep.2018.10.040. Epub 2018 Nov 9.
6
Analysis of Liver Microenvironment during Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish.分析斑马鱼非酒精性脂肪性肝病相关肝细胞癌早期进展过程中的肝微环境。
J Vis Exp. 2021 Apr 1(170). doi: 10.3791/62457.
7
Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma.肿瘤微环境的分子影像学评估局部治疗肝癌的效果。
Hepatol Commun. 2022 Apr;6(4):652-664. doi: 10.1002/hep4.1850. Epub 2021 Nov 5.
8
Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy.肝细胞癌的免疫相关方面：从早期检测的免疫标志物到免疫治疗
World J Gastrointest Oncol. 2021 Sep 15;13(9):1132-1143. doi: 10.4251/wjgo.v13.i9.1132.
9
Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo.原癌基因 FAM50A 可调控肝癌的免疫微环境及在体、体外发展。
Int J Mol Sci. 2023 Feb 6;24(4):3217. doi: 10.3390/ijms24043217.
10
A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment.基于肿瘤微环境中细胞表达谱的肝细胞癌分层模型。
BMC Cancer. 2022 Jun 4;22(1):613. doi: 10.1186/s12885-022-09647-5.

引用本文的文献

1
Immunity revealed: Stratifying hepatocellular carcinoma for precision immunotherapy.免疫揭秘：对肝细胞癌进行分层以实现精准免疫治疗。
Mol Ther Oncol. 2025 Feb 4;33(1):200939. doi: 10.1016/j.omton.2025.200939. eCollection 2025 Mar 20.
2
Efficacy of atezolizumab-bevacizumab combination therapy early after recurrence of hepatocellular carcinoma following resection or ablation with a curative intent.阿替利珠单抗联合贝伐单抗治疗根治性切除或消融术后肝细胞癌复发早期的疗效
Ann Gastroenterol. 2024 Nov-Dec;37(6):708-717. doi: 10.20524/aog.2024.0916. Epub 2024 Oct 20.
3
RAD51 High-Expressed Hepatocellular Carcinomas Are Associated With High Cell Proliferation.

本文引用的文献

1
The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities.巨噬细胞在非酒精性脂肪性肝病和原发性肝癌中的矛盾作用——挑战与机遇
Front Mol Biosci. 2023 Feb 10;10:1129831. doi: 10.3389/fmolb.2023.1129831. eCollection 2023.
2
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA.肝细胞癌的遗传学：从肿瘤到循环DNA
Cancers (Basel). 2023 Jan 28;15(3):817. doi: 10.3390/cancers15030817.
3
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.
RAD51 高表达的肝细胞癌与高细胞增殖相关。
J Surg Res. 2024 Oct;302:250-258. doi: 10.1016/j.jss.2024.07.046. Epub 2024 Aug 6.
4
γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy.γδ T 细胞：在肝细胞癌免疫治疗的未来中具有变革意义。
Int J Mol Sci. 2024 Jan 23;25(3):1381. doi: 10.3390/ijms25031381.
5
Reciprocal interactions between malignant cells and macrophages enhance cancer stemness and M2 polarization in HBV-associated hepatocellular carcinoma.恶性细胞与巨噬细胞之间的相互作用增强了乙型肝炎病毒相关性肝细胞癌中的癌症干细胞特性和 M2 极化。
Theranostics. 2024 Jan 1;14(2):892-910. doi: 10.7150/thno.87962. eCollection 2024.
6
Interplay of Extracellular Vesicles and TLR4 Signaling in Hepatocellular Carcinoma Pathophysiology and Therapeutics.细胞外囊泡与TLR4信号通路在肝细胞癌病理生理学及治疗中的相互作用
Pharmaceutics. 2023 Oct 13;15(10):2460. doi: 10.3390/pharmaceutics15102460.
7
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.肥胖与肝癌发生的十字路口会议：独特的病理生理途径为创新治疗方法带来期望。
Int J Mol Sci. 2023 Sep 28;24(19):14704. doi: 10.3390/ijms241914704.
8
The core role of macrophages in hepatocellular carcinoma: the definition of molecular subtypes and the prognostic risk system.巨噬细胞在肝细胞癌中的核心作用：分子亚型的定义及预后风险系统
Front Pharmacol. 2023 Aug 24;14:1228052. doi: 10.3389/fphar.2023.1228052. eCollection 2023.
9
Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma.肝细胞癌的突变图谱与精准医学
Cancers (Basel). 2023 Aug 23;15(17):4221. doi: 10.3390/cancers15174221.
10
Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation.揭示肝癌中 M1 和 M2 巨噬细胞的阴阳平衡：外泌体在肿瘤微环境和免疫调节中的作用。
Cells. 2023 Aug 10;12(16):2036. doi: 10.3390/cells12162036.
联合铁死亡诱导与髓系来源抑制细胞（MDSC）阻断可使肝脏原发肿瘤和转移灶对免疫检查点阻断敏感。
Gut. 2023 Sep;72(9):1774-1782. doi: 10.1136/gutjnl-2022-327909. Epub 2023 Jan 27.
4
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌的预后生物标志物
Cancers (Basel). 2022 Nov 26;14(23):5834. doi: 10.3390/cancers14235834.
5
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer.多区域单细胞剖析肿瘤和免疫细胞揭示肝癌中稳定的锁钥特征。
Nat Commun. 2022 Dec 7;13(1):7533. doi: 10.1038/s41467-022-35291-5.
6
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity.肝肿瘤免疫微环境亚型与中性粒细胞异质性
Nature. 2022 Dec;612(7938):141-147. doi: 10.1038/s41586-022-05400-x. Epub 2022 Nov 9.
7
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy.非酒精性脂肪性肝炎与肝细胞癌：免疫学与免疫治疗。
Clin Cancer Res. 2023 Feb 1;29(3):513-520. doi: 10.1158/1078-0432.CCR-21-1258.
8
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.肝癌免疫微环境：对肝细胞癌的治疗意义。
Hepatology. 2023 May 1;77(5):1773-1796. doi: 10.1002/hep.32740. Epub 2023 Apr 17.
9
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.晚期肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗的临床反应和耐药的分子相关性。
Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23.
10
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中长期肝细胞癌风险的分子特征。
Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474.